# US 7,608,409 B2 · Screening assay using G-protein coupled receptor protein OT7T175

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,409 B2
- Document ID: US7608409B2
- Status: Granted
- Kind: B2
- Application number: 11/976,414
- Filed: 2007-10-24
- Published: 2008-06-05
- Granted: 2009-10-27
- Earliest claimed: 1998-10-27
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Takuya Watanabe; Yasuko Terao; Yasushi Shintani; Tetsuya Ohtaki; Kimiko Kanehashi; Chieko Kitada
- Web page: https://patentgrep.com/patent/US7608409B2

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to rat cerebellum-derived and human brain-derived G protein coupled receptor proteins or salts thereof, their partial peptides, amides, esters or salts thereof, ligands to the same, a method/kit for screening compounds that alter the binding property between the ligands and the G protein coupled receptor proteins, compounds obtained by the screening or salts thereof, and antibodies to the G protein coupled receptor proteins.

## Claims

### Claim 1

A method for screening a compound or a salt thereof that alters the binding between a ligand and a protein, said method comprises:
contacting a protein with a ligand in the presence of a test compound, and
comparing the binding between said ligand and said protein to a control sample lacking the test compound and selecting the compound that alters said binding as compared to the control sample,
wherein said protein is selected from the group consisting of:
(i) the protein comprising the amino acid sequence of SEQ ID NO: 5;
(ii) the protein encoded by the nucleic acid sequence of SEQ ID NO: 6; and
(iii) the protein encoded by the nucleic acid sequence at least 95% homologous to SEQ ID NO: 6.